Cellectis SA
www.cellectis.com
Latest From Cellectis SA
Iovance TIL Appeal Seen Luring Potential Buyers
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.
Deal Watch: Conatus Ends NASH Ambitions, Merges With Regenerative Medicine Firm Histogen
Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.
Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
Servier To Tackle Parkinson's With Oncodesign Pact
A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Molecular Diversity
- Natural Products
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
France
-
France
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Cellectis SA
- Senior Management
-
Andre Choulika, PhD, CEO
Eric Dutang, CFO
Elsy Boglioli, COO
Philippe Duchateau, PhD, CSO
Stephane Depil, MD, PhD, SVP, R&D & CMO - Contact Info
-
Cellectis SA
Phone: (33) 81 69 16 00
8 rue de la Croix Jarry
Paris, 93235
France
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice